Compare · RVMD vs TWST
RVMD vs TWST
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $45.31B, about 4.5x TWST ($10.04B).
- TWST has been more active in the news (33 items in the past 4 weeks vs 11 for RVMD).
- RVMD has more recent analyst coverage (25 ratings vs 15 for TWST).
- Company
- Revolution Medicines Inc.
- Twist Bioscience Corporation
- Price
- $211.21-0.17%
- $151.63+7.80%
- Market cap
- $45.31B
- $10.04B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 11
- 33
- Recent ratings
- 25
- 15
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest RVMD
- General Counsel Cislini Jeff exercised 56,280 shares at a strike of $20.00 and sold $11,904,247 worth of shares (56,894 units at $209.24) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 55,907 units (SEC Form 4)
- Officer Goldsmith Mark A exercised 80,000 shares at a strike of $4.73 and sold $17,991,107 worth of shares (86,000 units at $209.20) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form SCHEDULE 13G filed by Revolution Medicines Inc.
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest TWST
- Officer Cho Dennis sold $222,227 worth of shares (1,598 units at $139.07), decreasing direct ownership by 2% to 74,063 units (SEC Form 4) to satisfy withholding tax
- President and COO Finn Patrick John sold $562,661 worth of shares (4,046 units at $139.07), decreasing direct ownership by 2% to 210,802 units (SEC Form 4) (tax withholding)
- Chief Accounting Officer Werner Robert F. sold $213,255 worth of shares (1,523 units at $140.02), decreasing direct ownership by 3% to 44,637 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Laponis Adam sold $273,265 worth of shares (1,965 units at $139.07), decreasing direct ownership by 2% to 108,633 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Leproust Emily M. sold $923,259 worth of shares (6,639 units at $139.07), decreasing direct ownership by 0.81% to 812,299 units (SEC Form 4) to satisfy tax liability
- SVP of Human Resources Green Paula sold $189,130 worth of shares (1,360 units at $139.07), decreasing direct ownership by 1% to 117,921 units (SEC Form 4) (tax withholding)
- Officer Cho Dennis sold $1,843,099 worth of shares (14,205 units at $129.75) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 75,661 units (SEC Form 4)
- President and COO Finn Patrick John exercised 23,355 shares at a strike of $67.85 and sold $9,217,607 worth of shares (78,355 units at $117.64) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 214,678 units (SEC Form 4)
- Twist Bioscience Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Twist Bioscience Corporation